Here’s what’s driving the multiple myeloma market

Advancements in newer therapies are expected to drive its expansion.

A rise in incident cases, expanded use of existing treatments, and increased research and development activities are driving the multiple myeloma market to witness substantial growth, said DelveInsight Business Research, LLP.

Advancements in newer therapies such as CAR-T cell therapies and bispecific antibodies are also expected to drive the sector’s expansion.

“Whilst current CAR-T treatments rely on a patient's own T cells (autologous), research is underway to develop allogeneic CAR-T cells sourced from healthy donors,” the report said.

In addition, the treatment landscape is shifting with the increasing adoption of monoclonal antibodies for newly diagnosed patients.